New drug duo aims to tackle lymphoma without chemo
NCT ID NCT05783609
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a combination of two drugs, epcoritamab and rituximab, can effectively treat follicular lymphoma in people who have not had any prior treatment. The trial will enroll about 100 adults with CD20-positive follicular lymphoma. The goal is to see how many patients achieve a complete metabolic response (no signs of active cancer) after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Epcoritamab and rituximab
What this could lead to
If successful, this combination could offer a more effective first-line treatment for follicular lymphoma, potentially leading to longer remission without chemotherapy.
What could go wrong
This is an early phase 2 trial with only 100 participants, so results may not apply to all patients. Side effects from the immune-based drugs could be significant, and the treatment may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
Contact
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Icahn School of Medicine at Mount Sinai Hospital
RECRUITINGNew York, New York, 10029, United States
Contact Email: •••••@•••••
Contact
-
Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Ohio State University Wexner Medical Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
-
University of Rochester Medical Center
RECRUITINGRochester, New York, 14642, United States
Contact Email: •••••@•••••